{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T04:19:55Z","timestamp":1785298795671,"version":"3.55.0"},"reference-count":52,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2011,7,1]],"date-time":"2011-07-01T00:00:00Z","timestamp":1309478400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["alz-journals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Alzheimer's &amp;amp; Dementia"],"published-print":{"date-parts":[[2011,7]]},"abstract":"<jats:p>The recruitment and retention of patients are among the greatest challenges currently being faced by researchers who conduct Alzheimer's disease (AD) clinical trials. To discuss these challenges and other major issues associated with clinical research in AD, an international workshop was organized by the Association Mon\u00c9gasque pour la recherche sur la Maladie d'Alzheimer at Monte Carlo, Monaco, in February 2010, with the participation of leading research experts in the field of Alzheimer's. Key topics discussed were as follows: (1) the selection, recruitment, and retention of clinical trial subjects; (2) international co\u2010operation among researchers; and (3) patient rights and informed consent for participants in clinical trials. This article highlights some of the challenges faced by investigators when conducting clinical trials in AD, and it also offers some recommendations aimed at overcoming these challenges.<\/jats:p>","DOI":"10.1016\/j.jalz.2010.05.2020","type":"journal-article","created":{"date-parts":[[2011,7,25]],"date-time":"2011-07-25T22:38:42Z","timestamp":1311633522000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["AMPA workshop on challenges faced by investigators conducting Alzheimer's disease clinical trials"],"prefix":"10.1002","volume":"7","author":[{"given":"Bruno","family":"Vellas","sequence":"first","affiliation":[{"name":"Department of Geriatrics INSERM U558 Toulouse University Hospital Center Toulouse France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Pesce","sequence":"additional","affiliation":[{"name":"Centre Hospitalier Princesse Grace Monaco Monaco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe H.","family":"Robert","sequence":"additional","affiliation":[{"name":"Centre M\u00c9moire CMRR Nice France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul S.","family":"Aisen","sequence":"additional","affiliation":[{"name":"Department of Neurosciences University of California San Diego CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Ancoli\u2010Israel","sequence":"additional","affiliation":[{"name":"Department of Psychiatry University of California San Diego San Diego CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandrine","family":"Andrieu","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Public Health University of Toulouse Toulouse France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesse","family":"Cedarbaum","sequence":"additional","affiliation":[{"name":"Elan Pharmaceuticals, Inc. South San Francisco CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Dubois","sequence":"additional","affiliation":[{"name":"Centre des Maladies Cognitives et Comportementales H\u00f4pital La Salp\u00eatri\u00e8re Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Siemers","sequence":"additional","affiliation":[{"name":"Alzheimer's disease research Eli Lilly and Company Indianapolis IN USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean\u2010Paul","family":"Spire","sequence":"additional","affiliation":[{"name":"Department of Neurology University of Chicago Chicago IL USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael W.","family":"Weiner","sequence":"additional","affiliation":[{"name":"Center for Imaging of Neurodegenerative Diseases San Francisco VA Medical Center San Francisco CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas S.","family":"May","sequence":"additional","affiliation":[{"name":"Independent Medical Writer Toronto Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2011,7]]},"reference":[{"key":"e_1_2_7_2_2","unstructured":"Alzheimer's Disease International.World Alzheimer report 2009. Available at:http:\/\/www.alz.co.uk\/research\/files\/World%20Alzheimer%20Report.pdf. Accessed March 22 2010."},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-2009-0971"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.57.4.613"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa013128"},{"key":"e_1_2_7_6_2","unstructured":"Janssen Pharmaceutica N.V. Belgium.Treatment of severe Alzheimer's disease: evaluation of efficacy and safety of galantamine hydrobromide in a controlled study. Available at:http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00216593. Accessed March 22 2010."},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(08)70261-8"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000266627.96040.5a"},{"key":"e_1_2_7_9_2","unstructured":"Forest Laboratories.An evaluation of the safety and efficacy of memantine in agitated patients with moderate to severe Alzheimer's disease. Available at:http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00097916. Accessed March 22 2010."},{"key":"e_1_2_7_10_2","unstructured":"New York University School of Medicine.Memantine and comprehensive individualized management of Alzheimer's disease and caregiver training. Available at:http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00120874. Accessed March 22 2010."},{"key":"e_1_2_7_11_2","unstructured":"East Kent Hospitals Trust.Memantine for Agitation in Dementia (MAGD). Available at:http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00371059. Accessed March 22 2010."},{"key":"e_1_2_7_12_2","unstructured":"PSAisen.Alzheimer's disease therapeutic research: the path forward. Available at:http:\/\/www.alzres.com\/content\/pdf\/alzrt2.pdf. Accessed March 22 2010."},{"key":"e_1_2_7_13_2","doi-asserted-by":"crossref","first-page":"289","DOI":"10.3233\/JAD-2008-15212","article-title":"Disease modifying trials in Alzheimer's disease: perspectives for the future","volume":"15","author":"Vellas B","year":"2008","journal-title":"J Alzheimers Dis"},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1072994"},{"key":"e_1_2_7_15_2","unstructured":"Sanofi\u2010Aventis.Study of Xaliproden (SR57746A) in patients with mild\u2010to\u2010moderate dementia of the Alzheimer's type. Available at:http:\/\/clinicaltrials.gov\/show\/NCT00104013. Accessed March 22 2010."},{"key":"e_1_2_7_16_2","unstructured":"TauRx Therapeutics Ltd.TRx0014 in patients with mild or moderate Alzheimer's disease. Available at:http:\/\/clinicaltrials.gov\/show\/NCT00515333. Accessed March 22 2010."},{"key":"e_1_2_7_17_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm0908-894"},{"key":"e_1_2_7_18_2","unstructured":"Bellus Health Inc.Evaluation of 3APS in patients with mild to moderate Alzheimer's disease. Available at:http:\/\/clinicaltrials.gov\/show\/NCT00088673. Accessed March 22 2010."},{"key":"e_1_2_7_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2009.07.038"},{"key":"e_1_2_7_20_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3181c67808"},{"key":"e_1_2_7_21_2","unstructured":"Myriad.Flurizan: Alzheimer's disease phase III clinical trial (USA). Available at:http:\/\/www.myriad.com\/research\/alzheimers\u2010disease\u2010clinical\u2010trial.php. Accessed March 22 2008."},{"key":"e_1_2_7_22_2","unstructured":"Myriad.Flurizan: Alzheimer's disease phase III clinical trial (global). Available at:http:\/\/www.myriad.com\/research\/alzheimers\u2010diseaseclinical\u2010trial\u2010global.php. Accessed March 22 2008."},{"key":"e_1_2_7_23_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2009.1866"},{"key":"e_1_2_7_24_2","unstructured":"RGThomas PSAisen SOBachurin LSeely DHung; dimebon investigators.Pfizer. a phase 3 study to evaluate the safety and tolerability of Dimebon patients with mild to moderate Alzheimer's disease. Available at:http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00838110. Accessed July 27 2010."},{"key":"e_1_2_7_25_2","unstructured":"Medivation Inc.Pfizer And Medivation announce results from two phase 3 studies in Dimebon (latrepirdine*) Alzheimer's Disease Clinical Development Program. Available at:http:\/\/investors.medivation.com\/releasedetail.cfm?releaseid=448818. Accessed July 27 2010."},{"key":"e_1_2_7_26_2","unstructured":"National Institute on Aging (NIA).DHA (docosahexaenoic acid) an omega 3 fatty acid in slowing the progression of Alzheimer's disease. Available at:http:\/\/clinicaltrials.gov\/show\/NCT00440050. Accessed March 22 2010."},{"key":"e_1_2_7_27_2","unstructured":"Eli Lilly and Company.Effect of LY450139 on the Long Term Progression of Alzheimer's Disease. Available at:http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00594568. Accessed July 27 2010."},{"key":"e_1_2_7_28_2","unstructured":"Wyeth.Study evaluating the safety and efficacy of bapineuzumab in Alzheimer disease patients. Available at:http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00676143?term=NCT0067614. Accessed March 22 2010."},{"key":"e_1_2_7_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(07)70109-6"},{"key":"e_1_2_7_30_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2008.683"},{"key":"e_1_2_7_31_2","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000260269.93245.d2"},{"key":"e_1_2_7_32_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.67.9_suppl_3.S6"},{"key":"e_1_2_7_33_2","doi-asserted-by":"publisher","DOI":"10.1002\/sim.1716"},{"key":"e_1_2_7_34_2","unstructured":"National Institute on Aging (NIA).Prevention of Alzheimer's disease by Vitamin E and Selenium (PREADVISE). Available at:http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00040378. Accessed March 22 2010."},{"key":"e_1_2_7_35_2","doi-asserted-by":"publisher","DOI":"10.3945\/ajcn.2009.29121"},{"key":"e_1_2_7_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2009.01.008"},{"key":"e_1_2_7_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2010.03.007"},{"key":"e_1_2_7_38_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12603-010-0064-3"},{"key":"e_1_2_7_39_2","doi-asserted-by":"publisher","DOI":"10.1067\/mcp.2001.113989"},{"key":"e_1_2_7_40_2","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jalz.2006.07.001","article-title":"Challenges to demonstrating disease\u2010modifying effects in Alzheimer's disease clinical trials","volume":"2","author":"Cumming JL","year":"2006","journal-title":"Alzheimers Dement"},{"key":"e_1_2_7_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.exger.2009.10.010"},{"key":"e_1_2_7_42_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroimage.2009.02.015"},{"key":"e_1_2_7_43_2","doi-asserted-by":"publisher","DOI":"10.1097\/WAD.0b013e31816c92bf"},{"key":"e_1_2_7_44_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(07)70178-3"},{"key":"e_1_2_7_45_2","first-page":"265","article-title":"Attrition in geriatric research: how important is it and how should it be dealt with?","volume":"11","author":"Gardette V","year":"2007","journal-title":"J Nutr Health Aging"},{"key":"e_1_2_7_46_2","volume-title":"Medical Epidemiology","author":"Greenberg RS","year":"2001"},{"key":"e_1_2_7_47_2","doi-asserted-by":"publisher","DOI":"10.1159\/000144087"},{"key":"e_1_2_7_48_2","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-2008-15214"},{"key":"e_1_2_7_49_2","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1007\/BF03028614","article-title":"Editorial: EADC (European Alzheimer Disease Consortium) recommendations for future Alzheimer disease research in Europe","volume":"12","author":"Winblad B","year":"2008","journal-title":"J Nutr Health Aging"},{"key":"e_1_2_7_50_2","unstructured":"Regents of the University of California.About the ADCS. Available at:http:\/\/www.adcs.org\/admin\/AboutADCS.aspx. Accessed March 22 2010."},{"key":"e_1_2_7_51_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2009.01.021"},{"key":"e_1_2_7_52_2","unstructured":"BVellas EReynish.EADC overview. Available at:http:\/\/www.eadc.info\/public\/pubblicazioni\/report_on_eadc.pdf. Accessed March 22 2010."},{"key":"e_1_2_7_53_2","doi-asserted-by":"publisher","DOI":"10.1353\/pbm.1995.0049"}],"container-title":["Alzheimer's &amp; Dementia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1552526010021850?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1552526010021850?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1016%2Fj.jalz.2010.05.2020","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1016\/j.jalz.2010.05.2020","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1016\/j.jalz.2010.05.2020","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/alz-journals.onlinelibrary.wiley.com\/doi\/pdf\/10.1016\/j.jalz.2010.05.2020","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T19:20:33Z","timestamp":1759951233000},"score":1,"resource":{"primary":{"URL":"https:\/\/alz-journals.onlinelibrary.wiley.com\/doi\/10.1016\/j.jalz.2010.05.2020"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,7]]},"references-count":52,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2011,7]]}},"alternative-id":["10.1016\/j.jalz.2010.05.2020"],"URL":"https:\/\/doi.org\/10.1016\/j.jalz.2010.05.2020","archive":["Portico"],"relation":{},"ISSN":["1552-5260","1552-5279"],"issn-type":[{"value":"1552-5260","type":"print"},{"value":"1552-5279","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,7]]},"assertion":[{"value":"2011-07-01","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}